Guardant Health pulls in sizable Series B for next-gen sequencing Dx; Foundation Medicine abandons plans to raise $150M;

> Guardant Health, a gene-sequencing-based diagnostics firm, has finished what has now become a $30 million Series B financing, in a round led by Khosla Ventures that also included Sequoia Capital and new investor Pejman Mar Ventures. Story (sub. req.)

> Diagnostics luminary Foundation Medicine ($FMI) has abandoned plans to raise $150 million in a secondary offering in the wake of a bearish market. Story

> Quest Diagnostics ($DGX) has completed its acquisition of prevention and wellness services outfit Summit Health. Story

> Boston Heart Diagnostics in Massachusetts has obtained its New York laboratory permit for diagnostic testing. The company produces next-generation tests for cardiovascular disease. Release

> Researchers found that a particular biomarker helped identify patients who might respond best to a specific melanoma treatment. Story

> North Carolina's Zenalux Biomedical will work with the Buffalo, NY-based Roswell Park Cancer Institute to enhance one of its devices for improved oral cancer detection. Release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.